Fundz
You are reading one round. Fundz also knows which of your own LinkedIn connections can open this account.See it live →

Circle Pharma announces $92.5 million Series E financing led by The Column Group to advance their Cyclin D1 program into clinical development.

PRIVATESep 16, 2026•about 3 hours ago

Amount Raised

$92.5 Million

Round Type

Series E

South San FranciscoHealthcare

Investors

Eli Lilly And CompanyEuclidean CapitalRa Capital ManagementNextech InvestThe Column Group

Description

Circle Pharma, a clinical-stage biopharmaceutical company, has successfully raised $92.5 million in an oversubscribed Series E financing. The funding was led by The Column Group with participation from existing and new investors including Nextech Invest, RA Capital Management, Euclidean Capital, and Eli Lilly. The proceeds will be used to advance their first-in-class Cyclin D1 program. This financing marks a significant step forward in their efforts to develop targeted macrocycle therapeutics for cancer.

Company Information

Company

Circle Pharma

Location

South San Francisco, California, United States

Don't miss Circle Pharma's next move

Get an email the moment Circle Pharma raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Circle Pharma's next move

See what Strategic adds

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Circle Pharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.